01-01-2009 | Review
Twenty-Five Years of Research on Saccharomyces boulardii Trophic Effects: Updates and Perspectives
Published in: Digestive Diseases and Sciences | Issue 1/2009
Login to get accessExcerpt
Saccharomyces boulardii (S. boulardii) was discovered by Henri Boulard in 1920 in Indochina. Since then, lyophilized preparations of S. boulardii have increasingly been used throughout the world, providing empirical evidence of its efficacy as an adjuvant agent to treat diarrhea and prevent antibiotic-associated complications. Since 1982, the year of the first publication [1], increasing numbers of studies have been conducted each year to determine the mechanism(s) of action of S. boulardii and to evaluate whether it has beneficial properties for the host organism. More recently, placebo-controlled, double-blind studies have demonstrated the efficacy of S. boulardii as a probiotic medication and as a biotherapeutic agent in some intestinal disorders in both children and adults. The target intestinal disorders are listen in Table 1 along with the corresponding references [2‐28]. The references listed here were selected from the MEDLINE database (NIH, National Library) from among 247 publications, including both clinical and experimental studies. The number of publications on S. boulardii has increased since the mid-1990s, now reaching 15 publications per year, while very recently meta-analyses have demonstrated the beneficial effects of S. boulardii treatment, mainly in Clostridium difficile-associated disease, antibiotic-associated diarrheas, and acute infectious diarrheas.
Disorder
|
References
|
---|---|
Diarrheas
|
|
Antibiotic-associated diarrhea
|
|
Acute infectious
|
|
Amebiasis
|
[7]
|
Acute and subacute giardiasis
|
[8]
|
Clostridium difficile enterocolopathies
|
|
Pseudomembranous enterocolitis
|
[12]
|
Traveler’s diarrhea
|
|
Acute Helicobacter pylori
|
|
Chronic persistent diarrhea
|
|
Chronic protracted diarrhea
|
[9]
|
AIDS-associated diarrhea
|
[18]
|
IBD
|
|
Crohn’s disease
|
[19]
|
Ulcerative colitis
|
[20]
|
Continuous enteral feeding
|
[21]
|
Critically ill tube-fed patients
|
[22]
|
Hirschsprung’s disease, enterocolitis
|
[23]
|
Pediatric age group
|
|
Prematures
|
[27]
|
Infants, children
|
|
Autism and diarrhea
|
[28]
|
Irritable bowel
|
[29]
|